Zobrazeno 1 - 10
of 52
pro vyhledávání: '"Stefan Hantel"'
Autor:
Anne Pernille Ofstad, Afshin Salsali, Erich Bluhmki, Martin Schumacher, Christoph Wanner, John M. Lachin, Silvio E. Inzucchi, Stefan Hantel, Kristin Ohneberg, Jyothis T. George, Claudia Schmoor, David Fitchett, Faiez Zannad, Bernard Zinman
Publikováno v:
ESC Heart Failure
ESC Heart Failure, Wiley, 2021, ⟨10.1002/ehf2.13615⟩
ESC Heart Failure, Vol 8, Iss 6, Pp 4517-4527 (2021)
ESC Heart Failure, 2021, ⟨10.1002/ehf2.13615⟩
ESC Heart Failure, Wiley, 2021, ⟨10.1002/ehf2.13615⟩
ESC Heart Failure, Vol 8, Iss 6, Pp 4517-4527 (2021)
ESC Heart Failure, 2021, ⟨10.1002/ehf2.13615⟩
International audience; Aims: In the EMPA-REG OUTCOME trial, empagliflozin reduced risk of death from heart failure (HF) or hospitalization for heart failure (HHF) versus placebo in patients with type 2 diabetes mellitus (T2DM) and established cardio
Autor:
Christoph Wanner, Isabella Zwiener, Robert J. Mentz, Jyothis T. George, Abhinav Sharma, David Fitchett, Nihar R. Desai, Bernard Zinman, Anne Pernille Ofstad, Stefan Hantel, Tariq Ahmad
Publikováno v:
JACC: Heart Failure. 9:568-577
Objectives Using latent class analysis (LCA) of EMPA-REG OUTCOME (BI 10773 [Empagliflozin] Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients), this study identified d...
Autor:
Stefan Kaspers, Stuart J. Pocock, Stefan D. Anker, Michaela Mattheus, Silvio E. Inzucchi, Søren S Lund, Maximilian von Eynatten, Christoph Wanner, Jyothis T. George, Waheed Jamal, Stefan Hantel, Bernard Zinman, Odd Erik Johansen, David Fitchett, Ulrich Elsasser, Darren K. McGuire
Publikováno v:
The Lancet Diabetes & Endocrinology. 8:949-959
Patients with type 2 diabetes and atherosclerotic cardiovascular disease are at high clinical risk. We assessed the effect of the sodium-glucose co-transporter-2 inhibitor, empagliflozin, on total cardiovascular events and admissions to hospital in t
Autor:
Christoph Wanner, David C. Wheeler, Audrey Koitka-Weber, Stefan Hantel, Maximilian von Eynatten, Jyothis T. George, Adeera Levin, Vlado Perkovic
Publikováno v:
Clin J Am Soc Nephrol
Background and objectives In the Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients (EMPA-REG Outcome), empagliflozin, in addition to standard of care, significantly reduced risk of cardiovascular death by 38%, hosp
Autor:
Elvira Toural, David Fitchett, Stefan Hantel, Jyothis T. George, Silvio E. Inzucchi, Pedro Monteiro, Sanja Giljanovic Kis, Bernard Zinman, Stefan Kaspers, Richard M. Bergenstal
Publikováno v:
Age Ageing
Objective The risks of cardio-renal complications of diabetes increase with age. In the EMPA-REG OUTCOME® trial, empagliflozin reduced cardiovascular (CV) mortality by 38% in patients with type 2 diabetes (T2D) and CV disease. Here we compare outcom
Autor:
Stefan Hantel, Matthew R. Weir, Audrey Koitka-Weber, Maximilian von Eynatten, Christoph Wanner, Gert Mayer, Bernard Zinman, Silvio E. Inzucchi, David Z.I. Cherney
Publikováno v:
Kidney International. 96:489-504
In patients with type 2 diabetes mellitus (T2DM) and cardiovascular (CV) disease, empagliflozin (EMPA) decreased progression of chronic kidney disease (CKD), likely via a reduction in intraglomerular pressure. Due to prevalent comorbidities, such as
Autor:
Stefan D. Anker, Bernard Zinman, Michaela Mattheus, Silvio E. Inzucchi, Stefan Hantel, Christoph Wanner, Ola Vedin, Søren S Lund, David Fitchett
Publikováno v:
Diabetes. 70
Autor:
Sd. Anker, Jyothis T. George, Stefan Kaspers, Bernard Zinman, David Fitchett, OE Johansen, Waheed Jamal, Stefan Hantel, C Wanner, Silvio E. Inzucchi, Stuart J. Pocock, SS Lund
Publikováno v:
Präzisionsmedizin – Eine Reise in die Zukunft der Diabetologie www.diabeteskongress.de.
Autor:
Christoph Wanner, Stefan Hantel, Maximilian von Eynatten, Tomoo Okamura, Masaomi Nangaku, Takashi Kadowaki, Audrey Koitka-Weber
Publikováno v:
Journal of Diabetes Investigation
Journal of Diabetes Investigation, Vol 10, Iss 3, Pp 760-770 (2019)
Journal of Diabetes Investigation, Vol 10, Iss 3, Pp 760-770 (2019)
Aims/Introduction In the EMPA‐REG OUTCOME® trial, empagliflozin added to standard of care improved clinically relevant kidney outcomes by 39%, slowed progression of chronic kidney disease, and reduced albuminuria in patients with type 2 diabetes a
Autor:
Odd Erik Johansen, Silvio E. Inzucchi, Waheed Jamal, Stefan Hantel, Stefan Kaspers, David Fitchett, Søren S Lund, Christoph Wanner, Bernard Zinman, Stuart J. Pocock, Stefan D. Anker, Jyothis T. George
Publikováno v:
Circulation. 142
Introduction: In EMPA-REG OUTCOME, empagliflozin (EMPA) reduced the risk of major adverse cardiovascular (CV) events (MACE), CV mortality and hospitalization for heart failure (HHF) in analyses of first events in patients with type 2 diabetes (T2D) a